Invalidity dossier
US 5317010
Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
Current assignee: Individual
Added 9/23/2026, 1:37:07 PM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US5317010A
Title: Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
Patent number: US5317010A (application US07/773,098)
Inventors: Peter K. T. Pang; Jie Shan
Assignee: Listed as "Individual" (current); an assignment dated 1991-12-10 records assignment to Pang, Peter K. T., with Shan, Jie as assignor.
Key dates (per the supplied record): Filed 1991-10-10; priority date 1991-10-10; granted/published 1994-05-31; anticipated expiration 2011-10-10. Legal status listed as "Expired – Lifetime." The source notes legal status and priority dates are assumptions, not legal conclusions. Related filings listed include JP5507124A, PCT/US1992/008477 (WO1993006845A1), AU28712/92A, EP92922071A, and CA002120946A.
Purpose and plain-language scope: The patent concerns parathyroid hormone (PTH) analogues that are substituted at amino acid positions 25, 26, and 27, and their use in treating osteoporosis. According to the source, the work addresses PTH effects beyond bone cells—including cardiac effects, blood pressure effects, chronotropic and inotropic effects, hypotension, and smooth-muscle relaxation—while describing PTH analogues, substitutions, and pharmaceutical compositions, including methods relating to bone disease and osteoporotic effects. The title and indexed keywords indicate the analogues are defined by substitutions at AA 25, 26, and 27 relative to PTH (e.g., human and bovine PTH appear in the indexed terms).
Source: https://patents.google.com/patent/[US5317010](/patent/US5317010)/en (fetched 2026-09-23)
What the excerpt does not establish:
- The complete claim language, claim count, or exact claimed substituents.
- The full specification, examples, or figures.
- Whether any particular PTH analogue is within or outside the claims.
- Any legal conclusion about validity, enforceability, inventorship, or current ownership.
Generated 10/1/2026, 9:52:58 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 5317010. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.